Open AccessProphylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus
Author(s) -
Michael W. Ferenczy
Publication year - 2007
Publication title -
current pharmaceutical design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 159
eISSN - 1873-4286
pISSN - 1381-6128
DOI - 10.2174/138161207781039779
Subject(s) - herpes simplex virus , adjuvant , vaccination , immune system , immunology , medicine , dna vaccination , virology , immunity , virus , asymptomatic , hsl and hsv , immunization , pathology
Herpes Simplex Virus Type 1 (HSV-1) infection is widespread and causes significant disease. A number of prophylactic vaccine strategies have elicited protective immunity in animal models, but no human vaccine has yet been effective. Asymptomatic HSV-1 infection is common, demonstrating that the immune system is able to control infection, despite failure to clear the virus. Therefore, therapeutic vaccination may be a viable strategy against HSV-1. This review will discuss the epidemiology, molecular biology, and immune response to HSV-1, prophylactic and therapeutic vaccine strategies, and the potential of future therapeutic HSV-1 vaccines to reduce or eliminate HSV-1 pathology.